FX1 disrupted the formation of the BCL6 repression complex, reactivated BCL6 target genes and suppressed ABC-DLBCL cells both in vitro and in vivo, as well as primary human ABC-DLBCL specimens (Cardenas et al., 2016). Here, BCL6 is linked to diffuse large B-cell lymphoma.